Oxford, UK – 15 August 2023 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-inflammation, today announces the appointment of Carrie Cook as its Chief Business Officer.
Carrie brings over 15 years of global business development experience driving expansion and growth at biotechnology and pharmaceutical companies across disease areas. At Sitryx, Carrie will join the Company’s senior management team where she will lead the Company’s global business development activities and help drive corporate strategy as Sitryx advances its pipeline of disease-modifying therapeutics in immuno-inflammation.
Neil Weir, Chief Executive Officer of Sitryx, said: “Carrie brings to Sitryx a wealth of experience supporting biotech and pharma companies, in both Europe and the US, to lead and execute portfolio and commercial opportunities and establish strategic partnerships with industry leaders across disease areas. Her expertise will be invaluable to Sitryx as we expand our global visibility and further develop relationships with pharma and biotech partners.”
Carrie Cook, Chief Business Officer of Sitryx, said: “Sitryx is at an exciting time in its development, and I look forward to working with Neil and the team to continue to build and strengthen Sitryx’s relationships with global leaders as the Company progresses its novel pipeline of immunometabolic therapies to treat a range of autoimmune and inflammatory diseases.”
Carrie joins Sitryx from Cerevance where, as Chief Business Officer, she led portfolio strategy, business development and alliance management. While at Cerevance she executed a $1.1 billion+ licensing agreement and research collaboration with Merck & Co. Prior to this, Carrie served as Senior Vice President/Global Head of Business Development at CANbridge Pharmaceuticals Inc. and was Senior Director, Center of External Innovation at Takeda Pharmaceuticals, where she secured a number of research and development agreements. Carrie has also held various business development and commercial planning roles of increasing responsibility at EMD Serono Inc., Merck Serono SA, Novartis Pharma AG and Baxter Healthcare SA. She holds an MBA from INSEAD and a B.A. in Biotechnology from Duke University in Durham, NC.
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-inflammation. Sitryx's proprietary science is led by a highly experienced management team and supported by world class academic founders. Sitryx was founded by six world-leading researchers in the field of immunology and metabolism; Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak. Together they have published more than 1,000 papers in the field, making multiple key breakthroughs in our understanding of how critical energetic status is to the behaviour of immune cells and in the broader field of immunology. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. In 2020, Sitryx formed an exclusive global licensing and research collaboration with Eli Lilly and Company. Lilly also became an investor in the Company. The Company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK. For more information, please visit www.sitryx.com.